Automated Pre-screening System for in meso Membrane protein crystallization
Automated Pre-screening System for in meso Membrane protein crystallization
批准号:
7762265
负责人:
Vadim Cherezov
金额:
$23.74万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-01-01 至 2012-11-30
关键词:
AchievementAdenosineAdenosine A2A ReceptorAdrenergic AgentsAdrenergic ReceptorAdverse effectsBehaviorBiological AssayBuffersCrystallizationDataDevelopmentDiffuseDiffusionDrug Delivery SystemsEventFailureFluorescence Recovery After PhotobleachingFluorescent ProbesFundingG-Protein-Coupled ReceptorsGoalsHandHumanImageIncubatedIntegral Membrane ProteinKnowledgeLabelLaboratoriesLasersLeadLicensingLipid BilayersLipidsMeasurementMeasuresMembrane ProteinsMethodologyMetricOutcomePharmaceutical PreparationsPhasePhysiological ProcessesPreparationProcessPropertyProtein FamilyProteinsProtocols documentationPublic HealthResearch Project GrantsResearch ProposalsResolutionSamplingScreening procedureSeriesSolutionsStagingStructureSurveysSystemTechniquesTechnologyTestingadrenergicbasedesigndrug developmentfluorescence microscopeheuristicsimprovedinterestnew technologyprotein aggregateprotein aggregationresearch studysuccessthree dimensional structurevisual feedback
中文摘要
描述(由申请人提供):结晶的膜蛋白在介晶中间相(中)是一种很有前途的技术,最近产生了高分辨率的结构,人类?2-肾上腺素能和腺苷A2A G蛋白偶联受体。介观结晶的一个显著特征是目的蛋白嵌入高度弯曲和折叠的空间脂质双层中,形成无规立方相。立方相的结构对大蛋白质或寡聚蛋白质聚集体的扩散施加空间约束。我们的初步数据表明,介观结晶试验失败的主要原因之一是由于快速的非特异性蛋白质聚集。对这种事件没有视觉反馈,立方相保持透明,因为非扩散的粘附蛋白质寡聚体的大小远低于100 nm。蛋白质的聚集行为取决于特定的蛋白质构建体、宿主脂质和用于结晶的添加剂。我们建议开发一个自动化系统进行光漂白后的荧光恢复(FRAP)的研究中膜蛋白。该系统将被用来开发一个预筛选试验,将使用不到10?L荧光标记的蛋白质溶液,以筛选与96种精心选择的常见沉淀剂溶液孵育的无水立方相中蛋白质的扩散。该测定的结果将有助于选择适合于内消旋结晶的蛋白质构建体,并从随后的结晶试验中消除某些沉淀物。这种结晶预筛选方法将显著增加获得初始晶体命中的机会,导致确定挑战性膜蛋白的更高分辨率结构,这对于设计具有更小副作用的新的和改进的高度特异性药物至关重要。
公共卫生解放(申请人提供):本研究项目将开发新技术,加快膜蛋白结晶的成功率。这些蛋白质参与重要的细胞和生理过程,因此是重要的药物靶标。结晶将促进蛋白质的三维结构的解决方案,为合理的药物开发过程提供必要的模板。
英文摘要
DESCRIPTION (provided by applicant): Crystallization of membrane proteins in lipidic mesophases (in meso) is a promising technique, which recently yielded high-resolution structures of human ?2-adrenergic and adenosine A2A G protein-coupled receptors. A distinct feature of the in meso crystallization is that the protein of interest is embedded into a highly curved and folded in space lipid bilayer, forming a lipidic cubic phase. The structure of the cubic phase imposes spatial constrains on diffusion of large proteins or oligomeric protein aggregates. Our preliminary data indicate that one of the primary reasons for failure of the in meso crystallization trials is due to a fast nonspecific protein aggregation. There is no visual feedback to such event, the cubic phase remains clear, because the size of the non-diffusing stuck protein oligomeric aggregates is well below 100 nm. The aggregation behavior of a protein depends on the particular protein construct, host lipid and additives employed for crystallization. We propose to develop an automated system for carrying out Fluorescence Recovery after Photobleaching (FRAP) studies of membrane proteins in meso. This system will be used to develop a pre-screening assay which will use less than 10 ?L of fluorescently labeled protein solution to screen for diffusion of the protein in the lipidic cubic phase incubated with 96 solutions of carefully selected common precipitants. The results of this assay will help to select suitable for in meso crystallization protein constructs and to eliminate certain precipitants from subsequent crystallization trials. Such crystallization pre-screening approach will significantly increase chances of obtaining initial crystal hit leading to the determination of more high-resolution structures of challenging membrane proteins essential in designing new and improved highly specific drugs with lesser side effects.
PUBLIC HEALTH RELEVENCE (provided by the applicant): This research project will develop new technologies that will accelerate the success rate of membrane protein crystallization. These proteins are involved in important cellular and physiological processes and therefore are important drug targets. Crystallization will facilitate solution of three-dimensional structures of the proteins providing necessary templates for the rational drug development process.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Non-addictive Angiotensin AT2 inhibitors for neuropathic pain relief
-
批准号:10396694
-
项目类别:
-
资助金额:$68.5万
-
财政年份:2020
-
负责人:Vadim Cherezov
-
依托单位:
Non-addictive Angiotensin AT2 inhibitors for neuropathic pain relief
-
批准号:10405661
-
项目类别:
-
资助金额:$64.76万
-
财政年份:2020
-
负责人:Vadim Cherezov
-
依托单位:
Non-addictive Angiotensin AT2 inhibitors for neuropathic pain relief
-
批准号:10645104
-
项目类别:
-
资助金额:$60.74万
-
财政年份:2020
-
负责人:Vadim Cherezov
-
依托单位:
Structural biology of G protein-coupled receptors
-
批准号:9925243
-
项目类别:
-
资助金额:$41.25万
-
财政年份:2018
-
负责人:Vadim Cherezov
-
依托单位:
Structural biology of G protein-coupled receptors
-
批准号:10396469
-
项目类别:
-
资助金额:$41.25万
-
财政年份:2018
-
负责人:Vadim Cherezov
-
依托单位:
Structure guided design of photoselectable channelrhodopsins
-
批准号:9244699
-
项目类别:
-
资助金额:$23.1万
-
财政年份:2016
-
负责人:Vadim Cherezov
-
依托单位:
Structure guided design of photoselectable channelrhodopsins
-
批准号:9360611
-
项目类别:
-
资助金额:$21.96万
-
财政年份:2016
-
负责人:Vadim Cherezov
-
依托单位:
HT structure determination of GPCRs by LCP serial femtosecond nanocrystallography
-
批准号:9078982
-
项目类别:
-
资助金额:$31.88万
-
财政年份:2014
-
负责人:Vadim Cherezov
-
依托单位:
In Situ Synthesis Of GPCR Ligands
-
批准号:8788814
-
项目类别:
-
资助金额:$24.73万
-
财政年份:2014
-
负责人:Vadim Cherezov
-
依托单位:
In Situ Synthesis Of GPCR Ligands
-
批准号:8620213
-
项目类别:
-
资助金额:$20.61万
-
财政年份:2014
-
负责人:Vadim Cherezov
-
依托单位:
HT structure determination of GPCRs by LCP serial femtosecond nanocrystallography
-
批准号:8612932
-
项目类别:
-
资助金额:$5.0万
-
财政年份:2014
-
负责人:Vadim Cherezov
-
依托单位:
CHARACTERIZATION OF NOVEL LCP MATRICES FOR MEMBRANE PROTEIN CRYSTALLIZATION BY S
-
批准号:8362309
-
项目类别:
-
资助金额:$0.52万
-
财政年份:2011
-
负责人:Vadim Cherezov
-
依托单位:
Molecular Mechanism of Allosteric Modulation of the Oxytocin Receptor by Sterols
-
批准号:8142783
-
项目类别:
-
资助金额:$35.72万
-
财政年份:2010
-
负责人:Vadim Cherezov
-
依托单位:
CHARACTERIZATION OF NOVEL LCP MATRICES FOR MEMBRANE PROTEIN CRYSTALLIZATION BY S
-
批准号:8170313
-
项目类别:
-
资助金额:$0.03万
-
财政年份:2010
-
负责人:Vadim Cherezov
-
依托单位:
Molecular Mechanism of Allosteric Modulation of the Oxytocin Receptor by Sterols
-
批准号:8537938
-
项目类别:
-
资助金额:$34.47万
-
财政年份:2010
-
负责人:Vadim Cherezov
-
依托单位:
Automated Pre-screening System for in meso Membrane protein crystallization
-
批准号:8009470
-
项目类别:
-
资助金额:$23.5万
-
财政年份:2010
-
负责人:Vadim Cherezov
-
依托单位:
Molecular Mechanism of Allosteric Modulation of the Oxytocin Receptor by Sterols
-
批准号:8727041
-
项目类别:
-
资助金额:$10.98万
-
财政年份:2010
-
负责人:Vadim Cherezov
-
依托单位:
Molecular Mechanism of Allosteric Modulation of the Oxytocin Receptor by Sterols
-
批准号:8328915
-
项目类别:
-
资助金额:$35.72万
-
财政年份:2010
-
负责人:Vadim Cherezov
-
依托单位:
Automated Pre-screening System for in meso Membrane protein crystallization
-
批准号:8197583
-
项目类别:
-
资助金额:$23.5万
-
财政年份:2010
-
负责人:Vadim Cherezov
-
依托单位:
Molecular Mechanism of Allosteric Modulation of the Oxytocin Receptor by Sterols
-
批准号:7985138
-
项目类别:
-
资助金额:$36.08万
-
财政年份:2010
-
负责人:Vadim Cherezov
-
依托单位:
国内基金
海外基金
基于ADK/Adenosine调控DNA甲基化探讨“利湿化瘀通络”法对2型糖尿病肾病足细胞裂孔膜损伤的干预机制研究
-
批准号:82074359
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2020
-
负责人:安晓飞
-
依托单位:
细胞外腺苷(Adenosine)作为干细胞旁分泌因子的生物学鉴定和功能分析
-
批准号:81570244
-
项目类别:面上项目
-
资助金额:57.0万元
-
批准年份:2015
-
负责人:丁兆平
-
依托单位:
Adenosine诱导A1/A2AR稳态失衡启动慢性低灌注白质炎性损伤及其机制
-
批准号:81171113
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2011
-
负责人:黄文
-
依托单位: